Quick Answer
Vanda Pharmaceuticals Inc. reported Total Revenue of $216.11 million for the year ending 2025.
- Vanda Pharmaceuticals Inc. showed an increase of +0.0% in Total Revenue from 2025 to 2025.
- This data is from Vanda Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2016 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $47.35 million | Q3 2018: $49.14 million | Q3 2018: $49.14 million | Q4 2018: $53.04 million | Q1 2019: $47.71 million | Q1 2019: $47.71 million | Q2 2019: $59.06 million | Q2 2019: $59.06 million | Q3 2019: $59.49 million | Q3 2019: $59.49 million | Q4 2019: $60.93 million | Q1 2020: $58.00 million | Q1 2020: $58.00 million | Q2 2020: $62.21 million | Q2 2020: $62.21 million | Q3 2020: $60.31 million | Q3 2020: $60.31 million | Q4 2020: $67.65 million | Q1 2021: $62.67 million | Q1 2021: $62.67 million | Q2 2021: $67.90 million | Q2 2021: $67.90 million | Q3 2021: $70.10 million | Q3 2021: $70.10 million | Q1 2022: $60.19 million | Q1 2022: $60.19 million | Q2 2022: $64.39 million | Q2 2022: $64.39 million | Q3 2022: $65.32 million | Q3 2022: $65.32 million | Q1 2023: $62.50 million | Q1 2023: $62.50 million | Q2 2023: $46.06 million | Q2 2023: $46.06 million | Q3 2023: $38.82 million | Q3 2023: $38.82 million | Q1 2024: $47.46 million | Q1 2024: $47.46 million | Q2 2024: $50.47 million | Q2 2024: $50.47 million | Q3 2024: $47.65 million | Q3 2024: $47.65 million | Q1 2025: $50.04 million | Q1 2025: $50.04 million | Q2 2025: $52.59 million | Q2 2025: $52.59 million | Q3 2025: $56.26 million | Q3 2025: $56.26 million.
- Over the full 19 years of available data (2016 to 2025), Vanda Pharmaceuticals Inc.'s Total Revenue has grown by 48.0%.
- Historical annual values: Fiscal year 2025: $216.11 million | Fiscal year 2025: $216.11 million | Fiscal year 2024: $198.77 million | Fiscal year 2024: $198.77 million | Fiscal year 2023: $192.64 million | Fiscal year 2023: $192.64 million | Fiscal year 2022: $254.38 million | Fiscal year 2022: $254.38 million | Fiscal year 2021: $268.68 million | Fiscal year 2021: $268.68 million | Fiscal year 2020: $248.17 million | Fiscal year 2020: $248.17 million | Fiscal year 2019: $227.19 million | Fiscal year 2019: $227.19 million | Fiscal year 2018: $193.12 million | Fiscal year 2018: $193.12 million | Fiscal year 2017: $165.08 million | Fiscal year 2017: $165.08 million | Fiscal year 2016: $146.02 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: